Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 8;115(2):122-124.
doi: 10.1093/jnci/djac212.

Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials

Patricia M LoRusso  1 , Boris Freidlin  2
Affiliations
Editorial

Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials

Patricia M LoRusso et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Rothmann MD, Zhang JJ, Lu L, et al.Testing in a prespecified subgroup and the intent-to-treat population. Drug Inf J. 2012;46(2):175-179. - PMC - PubMed
    1. Freidlin B, Korn EL.. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol. 2014;11(2):81-90. - PubMed
    1. Freidlin B, Korn EL.. A problematic biomarker trial design. J Natl Cancer Inst. 2022;114(2):187-190. - PMC - PubMed
    1. Tannock IF, Templeton AJ.. Flawed trials for cancer. Ann Oncol. 2020;31(3):331-333. - PubMed
    1. Kim MS, Prasad V.. Nested and adjacent subgroups in cancer clinical trials: when the best interests of companies and patients diverge. Eur J Cancer. 2021;155:163-167. - PubMed